Rigel receives positive trend vote from CHMP for fostamatinib disodium hexahydrate
Rigel Pharmaceuticals announced the CHMP of the EMA, has adopted a positive trend vote on the MAA for fostamatinib disodium hexahydrate (fostamatinib). The indication for positive trend vote is for treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments. October 18, 2019